Gynecologic Oncology | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics:

• Gynecologic Oncology
  • Introduction (0:00)

• Ovarian Cancer
  • PARP inhibitors as primary maintenance (8:11)
  • PARP inhibitors for recurrent and metastatic disease (19:04)
  • Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39)

• Endometrial Cancer
  • Immunotherapy for metastatic disease (43:49)
  • Selinexor as maintenance therapy (51:33)
  • Other novel agents (56:52)

• Cervical Cancer
  • Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00)

CME information and select publications